The ADC binds TROP2 (not topoisomerase I), is internalized, and releases a camptothecin-class topoisomerase I inhibitor that induces DNA damage and apoptosis in targeted (and nearby) cells; topoisomerase I is the intracellular enzyme inhibited by the payload, not the surface target of the drug.